Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.
Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving ≥2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.
Adding induction chemotherapy (IC) with gemcitabine and cisplatin (GP) to a backbone of cisplatin-based chemoradiotherapy (CRT) generated favourable recurrence-free survival (RFS) and overall survival (OS) rates and toxicity profile in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), according to data presented at ASCO 2019.
Patients with metastatic pancreatic cancer who carry a germline BRCA1/2 mutation may have their risk of disease progression almost halved with olaparib maintenance therapy following first-line treatment with platinum-based chemotherapy, according to results of the phase III POLO trial reported at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.